Episode 505: A Breakthrough in Cholesterol Care With an Oral PCSK9 Inhibitor

Heart Doc VIP with Dr. Joel Kahn by Dr. Joel Kahn

Jul 21, 202623:30Health

This week, Dr. Kahn discusses the FDA approval of the first oral PCSK9 inhibitor, Lipfendra (enclicitide), taken as a 20 mg daily tablet. In a study of nearly 3,000 patients with elevated LDL cholesterol despite treatmen...

Related Episodes

Continue listening to more episodes from Heart Doc VIP with Dr. Joel Kahn.

Episode 514: Blockbuster News About Lipoprotein(a) Therapy

Sep 8, 2026 - 29:53

This week, Dr. Kahn discusses the widespread disappointment following Novartis' announcement that its 8,0...

Episode 513: The Emerging Science of Pomegranates and Urolithin A

Sep 4, 2026 - 26:52

Dr. Kahn interviews Anurag Singh, MD, PhD, Chief Medical Officer of Timeline Nutrition , whose research h...

Episode 512: How Common Is Silent Atherosclerosis? More Common Than You Think

Sep 1, 2026 - 27:53

This week, Dr. Kahn reviews several important studies presented at the European Society of Cardiology Con...

Episode 511: Vascular Disease at Age 23 (Protect Our Young)

Aug 25, 2026 - 27:41

This week, Dr. Kahn returns to one of his passion topics: educating young people about healthy lifestyles...

Episode 510: The TG/HDL Ratio and Your Risk of Disease

Aug 18, 2026 - 26:56

This week, Dr. Kahn discusses the triglyceride-to-HDL (TG/HDL) ratio and how this simple lab measurement...

Episode 509: How to Upgrade Your Gene Activity in 4 Weeks

Aug 11, 2026 - 25:28

This week, Dr. Kahn discusses new research showing that after just 4 weeks of eating a whole-food, plant-...

Episode 508: Why Cooking to Reduce AGE Content Is a Healthy Habit

Aug 4, 2026 - 30:22

This week, Dr. Kahn discussed new research on advanced glycation end-products (AGEs) and cooking methods....

Episode 507: The Nuance of How Much Dietary Protein for Optimal Health

Jul 28, 2026 - 22:45

This week, Dr. Kahn discusses new data from the amazing Valter Longo, PhD, and his colleagues regarding o...